The biotech industry is rapidly expanding, and with it comes the need for innovative and well-equipped lab and office spaces. As a developer in this industry, it's essential to stay ahead of the curve and provide the best possible amenities to attract and retain tenants. One such amenity that has proven to be invaluable in this regard is a Mispro contract vivarium (CV).
A contract vivarium is a specialized facility for preclinical animal studies where biosciences companies can rent shared or private lab space and holding rooms necessary for early-stage in vivo research. In addition to access to fully equipped state-of-the-art research space, the CV supports its clients with comprehensive laboratory animal services including husbandry, veterinary, technical, and regulatory compliance oversight.
A contract vivarium is a specialized facility for preclinical animal studies where biosciences companies can rent shared or private lab space and holding rooms necessary for early-stage in vivo research.
Along with the lab and office space at your biotech property, partnering with Mispro to offer a contract vivarium on your campus provides your tenants with all the necessary infrastructure for the preclinical drug development phases, which typically last around 8 years for most biotech companies. As these companies achieve milestones, win additional funding, and expand, they will require more space and longer lease terms.
Mispro’s CV network – and the CV model, in general – is gaining unprecedented adoption in the industry as bio development accelerates in both well-known and newer bio clusters. In markets such as Boston-Cambridge, SanFrancisco Bay Area, San Diego, Philadelphia, and New York, where life sciences real estate development and inventory are booming, the addition of a contract vivarium to your property or campus can be a game-changer.
Let's take a closer look at Boston-Cambridge, for example.This market is home to 28.5 million square feet of life sciences inventory, with a vacancy rate of just 2.6%. Under construction are 4.4 million square feet, highlighting the continued demand for life sciences real estate. In this highly competitive market, having a Mispro contract vivarium on your campus can give you a significant advantage in attracting and retaining top biotech companies.
The same is true for the San Francisco Bay Area, which has a total life sciences inventory of 37.3 million square feet and is under construction with 7.4 million square feet. Having a contract vivarium on your campus in this market can be a critical component in staying ahead of the competition.
In this highly competitive market, having a Mispro contract vivarium on your campus can give you a significant advantage in attracting and retaining top biotech companies.
A contract vivarium not only offers competitive advantages in attracting high-value tenants to your property or campus but is also a high-value tenant itself, requiring only small footprints and standard infrastructure specifications for bio buildings while typically entering into a long-term lease.
Lastly, and importantly, partnering with a contract vivarium organization (CVO) ensures that the animal research conducted in their facility is ethical and humane. Mispro is committed to upholding the highest standards of animal care and welfare, ensuring that all animals are treated with respect and compassion.
In conclusion, if you are a developer in the biotech industry and offer lab and office space for biosciences companies, the addition of a CV to your property or campus can be a significant draw for tenants. By partnering with Mispro, you can provide researchers with access to world-class preclinical vivarium lab facilities while ensuring that all animal research conducted on your campus is ethical and humane.
Mispro designs, builds, and operates AAALAC-accredited full-service contract vivarium lab facilities where biosciences companies of all sizes and therapeutic indications can conduct and control their own preclinical in vivo rodent studies. Mispro ensures that their vivarium facilities are inspected regularly and that all research conducted in their facilities is compliant, ethical, and humane.
Sources: JLL "Biotech 2021: A Mid-Year Review"; CBRE "2021 Life Sciences Outlook"; Cushman & Wakefield "2021Biopharma Outlook"